Abeona Therapeutics (NASDAQ:ABEO) executives said the company is seeing growing patient demand for ZEVASKYN, an autologous cell-based gene therapy approved in April 2025 for adults and pediatric ...
Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...
As the demand for biologics accelerates, biopharma companies are under pressure to expand sterile manufacturing capacity ...
BASED cleanroom engineering company Total Clean Air (TCA), a UKAS ISO 17025-accredited cleanroom constructor, has been appointed European partner for US-based decontamination technology firm ...
Abeona Therapeutics Inc (ABEO) reports growing patient demand and significant financial gains, despite facing operational hurdles in launching its groundbreaking gene therapy.
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2025 Earnings Call Transcript March 17, 2026 Abeona Therapeutics Inc. beats ...
Good morning, everyone, and welcome to the Abeona Therapeutics Full Year 2025 Results Conference Call. [Operator Instructions] Please note this conference is being recor ...
Under this new agreement, TCA becomes the primary partner for sales, service, and technical support across the United Kingdom and the European Union. This collaboration creates a streamlined ...
ZIBO CITY, SHANDONG PROVINCE, CHINA, March 5, 2026 /EINPresswire.com/ -- The global veterinary pharmaceuticals market ...
Barclays 28th Annual Global Healthcare Conference March 11, 2026 3:30 PM EDTCompany ParticipantsNicholas Keher ...
Effective sterility testing is a crucial component in the manufacturing of life-saving drugs and therapies, ensuring that ...
Abeona Therapeutics has made significant strides in the fourth quarter of 2025, with its groundbreaking gene therapy, ZEVASKYN, experiencing growing patient demand. As reported during the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results